Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARC...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Diabetes Care
Egile Nagusiak: Docherty, Kieran F., Jhund, Pardeep S., Bengtsson, Olof, DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Martinez, Felipe A., Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., McMurray, John J.V.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Diabetes Association 2020
Gaiak:
Novel Communications in Diabetes
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7809714/
https://ncbi.nlm.nih.gov/pubmed/33082245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc20-1402
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak